NCT02387697View on ClinicalTrials.gov

Treatment of Severe Secondary TRIcuspid Regurgitation in Patients With Advance Heart Failure With CAval Vein Implantation of the Edwards Sapien XT VALve (TRICAVAL)

PHASE2/PHASE3TerminatedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

May 31, 2018

Study Completion Date

May 31, 2018

Conditions
Severe Tricuspid Regurgitation
Interventions
DEVICE

Edwards Sapien XT Valve

The device will be implanted in the present study to prevent abdominal venous congestion and to improve the function of the tricuspid valve which is located in the low pressure system in the right heart.

Trial Locations (1)

10117

Charite Universitaetsmedizin, Medizinische Klinik für Kardiologie und Angiologie, Berlin

Sponsors

Collaborators (1)

Edwards Lifesciences
All Listed Sponsors
collaborator

Edwards Lifesciences

INDUSTRY

lead

Charite University, Berlin, Germany

OTHER